CDT Equity Inc（CDT）資訊與事件CDTCDT Equity Inc

CDT Equity Appoints James Bligh as CEO

CDT Equity announced the appointment of James Bligh, co-founder of Conduit Pharmaceuticals, as CEO. Andrew Regan has been appointed as CEO of Sarborg Limited. CDT holds a 22% strategic investment in Sarborg and intends to continue working closely with the company as it develops its signature intelligence platform, expands its proprietary intellectual property portfolio and advances Sarborg.

CDT Equity Introduces New Solid Drug Forms, Enhancing Stability and Solubility

CDT Equity announced that new solid forms and alternative crystal structures of its existing drug compounds, show enhanced physical property advantages, including improved stability, solubility, manufacturability, over existing forms of these compounds. These solid forms are patent-protected under the company's substance of matter IP and could support new formulations tailored to specific patient needs, prospectively increasing the commercial life of the underlying assets. CDT has filed patents to protect these findings. CDT will now advance these findings into clinically relevant, lab models, building out further experimental evidence of biological activity and therapeutic potential, ahead of partnering discussions. CDT will also assess whether its proprietary solid forms can produce differentiated, competitive products, distinct from existing marketed formulations.

CDT Equity Enters SAFE Note with Pep'd Inc.

CDT Equity announced that it has entered into a SAFE note with Pep'd Inc., a US-based peptide company. Upon Pep'd closing an equity financing, this SAFE will automatically convert into a number of shares of safe preferred stock, depending on the Pep'd capitalization at that time and a valuation cap of $10M.